Clinical Trial Update: GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Genmab's GEN3014 trial in relapsed or refractory hematologic malignancies (relapsed/refractory multiple myeloma, diffuse large B cell lymphoma, and acute myeloi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Or Refractory Multiple Myeloma

Drugs mentioned

• GEN3014

Snippet

Sponsor: Genmab | Conditions: Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1, Phase 2 | Status: TERMINATED